Oncogene

Oncternal Therapeutics Announces Opening of Phase 1b Expansion Cohort of Clinical Trial of TK216, Targeted ETS Inhibitor, in Patients with Ewing Sarcoma

Retrieved on: 
Wednesday, December 11, 2019
Oncology, Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Neoplasms, Sarcoma, Transcription factors, Ewing's sarcoma, RTT, FUS, Oncogene, ERG, TK216, the Study, Oncternal Therapeutics

The expansion cohort will further evaluate the recommended Phase 2 dose regimen of TK216 (200 mg/m2/day for 14 days) in combination with vincristine and is anticipated to enroll approximately 18 patients with relapsed or refractory Ewing sarcoma.

Key Points: 
  • The expansion cohort will further evaluate the recommended Phase 2 dose regimen of TK216 (200 mg/m2/day for 14 days) in combination with vincristine and is anticipated to enroll approximately 18 patients with relapsed or refractory Ewing sarcoma.
  • TK216 is an investigational, potentially first-in-class, targeted small-molecule inhibitor of the E26 transformation-specific (ETS) family of oncoproteins including fusion proteins.
  • Tumorigenic fusion proteins involving the EWS protein and an ETS protein can be found in most cases of Ewing sarcoma.
  • The U.S. Food and Drug Administration (FDA) has granted Orphan Designation and Fast Track designation to TK216 for the treatment of Ewing sarcoma.

Entrectinib (Roche/Chugai/Nerviano): Global Drug Overview & Outlook with Sales for Non-small Cell Lung Cancer (NSCLC) by Country 2017-2026 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 5, 2019
Health, Oncology, Chemical compounds, Tyrosine kinase receptors, Organic compounds, Entrectinib, ROS1, Anaplastic lymphoma kinase, Trk receptor, Tropomyosin receptor kinase B, Protein kinase inhibitor, Tyrosine kinase, Oncogene, Kinase

Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins.

Key Points: 
  • Entrectinib (Roche/Chugai/Nerviano) is a selective tyrosine kinase inhibitor (TKI) of the tropomyosin receptor kinases (Trk) A, B, and C; ROS1; and anaplastic lymphoma kinase (ALK) proteins.
  • Under normal conditions, these oncogenes regulate the flow of cellular growth signaling.
  • However, mutations or molecular alterations can result in overactivity, setting off a signal cascade that drives uncontrolled proliferation.
  • In vivo models of entrectinib in TrkB expressing neuroblastoma cells suggest that the drug may enhance the efficacy of conventional chemotherapy.

Black Diamond Therapeutics Appoints Industry Veteran as Chief Operating Officer and General Counsel

Retrieved on: 
Wednesday, May 29, 2019
Carcinogenesis, Evolutionary biology, Branches of biology, Cancer, RTT, Oncogene, Mutation, Biology

In this role, he will oversee operations and all business and legal functions as Black Diamond transitions into a clinical-stage company.

Key Points: 
  • In this role, he will oversee operations and all business and legal functions as Black Diamond transitions into a clinical-stage company.
  • He joins Black Diamond from Radius Health, Inc., where he was Senior Vice President, General Counsel and Corporate Secretary.
  • Sanna joined Black Diamond from Mersana Therapeutics where she was Senior Director of Finance overseeing the organization's finance function.
  • Black Diamond pioneered the development of selective medicines for patients with genetically defined cancers driven by oncogenes activated by allosteric mutations.